Can advanced non-small-cell lung cancer be treated with weekly instead of 3-weekly docetaxel?

被引：3
|
作者：
Scagliotti, G. V. [1 ]
机构：
[1] Univ Turin, Dept Clin & Biol Sci, S Luigi Hosp Reg Gozole 10, I-10043 Turin, Italy
[2] S Luigi Hosp, Thorac Oncol Unit, Turin, Italy
来源：
NATURE CLINICAL PRACTICE ONCOLOGY | 2006年 / 3卷 / 06期
关键词：
docetaxel; non-small-cell lung cancer; schedule; survival; toxicity;
D O I：
10.1038/ncponc0510
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：294 / 295
页数：2
相关论文
共 50 条
  • [1] Can advanced non-small-cell lung cancer be treated with weekly instead of 3-weekly docetaxel?
    Giorgio V Scagliotti
    Nature Clinical Practice Oncology, 2006, 3 : 294 - 295
  • [2] Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel
    Schuette, W
    Nagel, S
    Blankenburg, T
    Lautenschlaeger, C
    Hans, K
    Schmidt, EW
    Dittrich, I
    Schweisfurth, H
    von Weikersthal, LF
    Raghavachar, A
    Reissig, A
    Serke, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (33) : 8389 - 8395
  • [3] Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer:: a Spanish Lung Cancer Group trial
    Camps, C
    Massuti, B
    Jiménez, A
    Maestu, I
    Gómez, RG
    Isla, D
    González, JL
    Almenar, D
    Blasco, A
    Rosell, R
    Carrato, A
    Viñolas, N
    Batista, N
    Girón, CG
    Galán, A
    López, M
    Blanco, R
    Provencio, M
    Diz, P
    Felip, E
    ANNALS OF ONCOLOGY, 2006, 17 (03) : 467 - 472
  • [4] Weekly versus 3-weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer (NSCLC): Meta-analysis of phase III trials
    Bria, Emilio
    Cuppone, Federica
    Ciccarese, Mariangela
    Carlini, Paolo
    Nistico, Cecilia
    Natoli, Guido
    Nuzzo, Carmen
    Terzoli, Edmondo
    Cognetti, Francesco
    Giannarelli, Diana
    ANNALS OF ONCOLOGY, 2006, 17 : 223 - 223
  • [5] Low-Dose Weekly Docetaxel Is as Tolerable as Pemetrexed in Previously Treated Advanced Non-Small-Cell Lung Cancer
    Chung, Fu-Tsai
    Lee, Kang-Yun
    Fang, Yueh-Fu
    Shieh, Meng-Heng
    Lin, Shu-Min
    Yu, Chih-Teng
    Lo, Yun-Lun
    Lin, Ting-Yu
    Kuo, Chih-Hsi
    Feng, Po-Hao
    Ni, Yung-Lun
    Kuo, Han-Pin
    CHEMOTHERAPY, 2011, 57 (02) : 147 - 155
  • [6] Comparison of weekly and 3-weekly schedule of docetaxel as second line treatment of advanced non-small-cell lung cancer (NSCLC): A meta-analysis of individual data from 818 patients
    Di Maio, M.
    Perrone, F.
    Chiodini, P.
    Gallo, C.
    Camps, C.
    Quoix, E.
    Schuette, W.
    Gridelli, C.
    ANNALS OF ONCOLOGY, 2006, 17 : XI25 - XI25
  • [7] Does weekly docetaxel improve survival over 3-weekly as second line chemotherapy for advanced non-small-cell lung cancer (NSCLC)? Meta-analysis of phase III trials
    Bria, E.
    Cuppone, F.
    Ciccarese, M.
    Carlini, P.
    Nistico, C.
    Natoli, G.
    Nuzzo, C.
    Terzoli, E.
    Cognetti, F.
    Giannarelli, D.
    ANNALS OF ONCOLOGY, 2006, 17 : XI19 - XI19
  • [8] WEEKLY PACLITAXEL VERSUS THE STANDARD 3-WEEKLY SCHEDULE IN PATIENTS WITH NON-SMALL CELL LUNG CANCER
    Halim, I. Abdel
    El-Ashry, M.
    El-Sadda, W.
    Temraz, S.
    ANNALS OF ONCOLOGY, 2012, 23 : 398 - 398
  • [9] Weekly chemotherapy of cisplatin and docetaxel for elderly patients with non-small-cell lung cancer
    Ohe, Y
    Niho, S
    Minami, H
    Saijo, N
    Watanabe, K
    Yokoyama, A
    Nishiwaki, Y
    LUNG CANCER, 2004, 45 : S76 - S77
  • [10] Phase II study of weekly docetaxel combined with cisplatin in patients with advanced non-small-cell lung cancer
    Tsunoda, T
    Koizumi, T
    Hayasaka, M
    Hirai, K
    Koyama, S
    Takabayashi, Y
    Fujimoto, K
    Kubo, K
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 54 (02) : 173 - 177
12345